<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577511</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2011/JFB-01</org_study_id>
    <secondary_id>2011-A01141-40</secondary_id>
    <nct_id>NCT01577511</nct_id>
  </id_info>
  <brief_title>Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer</brief_title>
  <official_title>Invasiveness and Chemoresistance of Cancer Stem Cells in Colon Cancer: Molecular Characterization and Implications for Therapeutic Strategies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to identify and characterize subpopulations of cells with&#xD;
      invasive capacity in colorectal cancer from primary tumor, blood and metastatic samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives include:&#xD;
&#xD;
        -  Determine the intrinsic properties essential for the dissemination and chemoresistance&#xD;
           of these cells capable of initiating tumors&#xD;
&#xD;
        -  Identify a &quot;molecular signature&quot; for potential invasiveness and chemoresistance of cells&#xD;
           initiating metastases.&#xD;
&#xD;
        -  Describe the evolution of patients during 24 months of follow up and correlations with&#xD;
           observed cellular profiles.&#xD;
&#xD;
        -  Enrich the tumor bank of the institution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2012</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ability to maintain the cells isolated from colorectal tumors in culture or 3D collagen matrices and then infect these cells to make them express reporter genes: yes/no.</measure>
    <time_frame>Baseline (Day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serology HIV</measure>
    <time_frame>baseline; day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology Hepatitis B</measure>
    <time_frame>baseline; day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology Hepatitis C</measure>
    <time_frame>baseline; day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location of primary tumor</measure>
    <time_frame>base line; day 0</time_frame>
    <description>right colon, left colon, transverse colon, sigmoid, rectum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age at diagnosis</measure>
    <time_frame>baseline, day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastases from the outset: Yes / No</measure>
    <time_frame>baseline, day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection proposed: yes/no</measure>
    <time_frame>baseline, day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy proposed? yes/no</measure>
    <time_frame>baseline, day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of metastases</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection performed: yes/no</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of chemotherapy sessions performed</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumoral response to treatment? yes/no</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor recurrence: yes/no</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status</measure>
    <time_frame>24 months</time_frame>
    <description>living/deceased</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to establish tumor xenografts from injected cells: yes/no.</measure>
    <time_frame>baseline; Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to detect subpopulations of tumor cells expressing fluorophores by flow cytometry after isolation: yes/no</measure>
    <time_frame>baseline; day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of mRNA expression profiling and micro-RNA + in vitro EMT cells</measure>
    <time_frame>baseline; day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organisation Score</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor staging</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of surgeries performed</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of circulating cancer cells per ml blood</measure>
    <time_frame>baseline; day 0</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>30 Patients</arm_group_label>
    <description>Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.&#xD;
Intervention: Samples and follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Samples and follow up</intervention_name>
    <description>Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.&#xD;
Follow-up: disease outcomes assessed at 24 months</description>
    <arm_group_label>30 Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peroperative blood sample plus primary and metastatic tumor biopsies.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the&#xD;
        Nîmes University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given his/her informed and signed consent&#xD;
&#xD;
          -  The patient must be insured or beneficiary of a health insurance plan&#xD;
&#xD;
          -  Patient with adenocarcinoma-type colorectal cancer:&#xD;
&#xD;
          -  stage III at diagnosis, surgical resection of the primary tumor proposed.&#xD;
&#xD;
          -  stage IV at diagnosis, surgical resection of the primary tumor and possibly of&#xD;
             metastases proposed.&#xD;
&#xD;
          -  Stage IV who have already undergone surgical excision of the primary tumor, and for&#xD;
             whom metastasectomy is now proposed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient is participating in another study&#xD;
&#xD;
          -  The patient is in an exclusion period determined by a previous study&#xD;
&#xD;
          -  The patient is under judicial protection, under tutorship or curatorship&#xD;
&#xD;
          -  The patient refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to correctly inform the patient&#xD;
&#xD;
          -  Patients for whom surgical resection of the primary tumor is not considered as an&#xD;
             option&#xD;
&#xD;
          -  PStage IV at diagnosis, but metastasectomy is not considered as an option&#xD;
&#xD;
          -  Patients with positive HIV, Hepatitis B or Hepatitis C serology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François Bourgaux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <state>Gard</state>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 12, 2012</study_first_submitted>
  <study_first_submitted_qc>April 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>invasive potential</keyword>
  <keyword>molecular characterisation of circulating cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

